

Title (en)
CATIONIC LIPID COMPOUNDS AND USE THEREOF FOR TRANSFERRING NEGATIVELY CHARGED SUBSTANCES OF THERAPEUTIC INTEREST

Title (de)
KATIONISCHE LIPIDMOLEKÜLE UND DEREN VERWENDUNG ZUR TRANSFEKTION NEGATIV GELADENER THERAPEUTISCHER VERBINDUNGEN

Title (fr)
COMPOSES LIPIDIQUES CATIONIQUES ET LEUR UTILISATION POUR LE TRANSFERT DE SUBSTANCES D'INTERET THERAPEUTIQUE CHARGEES NEGATIVEMENT

Publication
EP 1218033 A2 20020703 (FR)

Application
EP 00956608 A 20000803

Priority
• FR 0002234 W 20000803
• FR 9910141 A 19990804

Abstract (en)
[origin: FR2797188A1] The invention concerns the use of a monocationic lipid compound of general formula I(A): $R1O-CO-NH-(CH_2)_n-N^{+}(C_2H_5)_3$, I<-> wherein: R1 represents the cholesteryl radical; n represents an integer equal to 1, 2 or 3 and in particular 3- beta [N-(N',N',N'-triethylaminopropane iodide)-carbamoyl] cholesterol (TEAPC-Chol) and/or a monocationic lipid compound of general formula I(B): $R2-CO-NH-(CH_2)_n-N^{+}(R)_3, X^{<->}$ wherein: R2 represents in particular the abietic acid radical, or the radical of a derivative of cholanic (cholic, deoxycholic, dehydrocholic, lithocholic) acid; R represents in particular a methyl or ethyl radical; n represents an integer equal to 2 or 3; X represents in particular a chlorine or iodine atom; and/or a dicationic lipid compound of general formula II(A): $R1O-CO-N[CH_2-CH_2-N^{+}(R)_3, X^{<->}]_2$; and/or a dicationic lipid compound of general formula II(B): $R1O-CO-CH_2-CH_2-CO-N[CH_2-CH_2-N^{+}(R)_3, X^{<->}]_2$; and/or a dicationic lipid compound of formula II(C): $R2-CO-N[CH_2-CH_2-N^{+}(R)_3, X^{<->}]_2$ wherein R1 represents the cholesteryl radical; R2 represents in particular the abietic acid radical or the radical of a derivative of a cholanic (cholic, deoxycholic, dehydrocholic, lithocholic) acid; R represents in particular a hydrogen atom, a methyl or ethyl radical; X represents in particular a chlorine or iodine atom. Said compounds are useful for transfecting living organisms *in vivo*, organs *in vivo*, tumours *in vivo*, or cells in *vitro* or *ex vivo*.

IPC 1-7
A61K 47/48; **A61K 48/00**; **A61K 33/20**; **A61K 33/18**; **A61K 9/127**; **A61K 31/575**; **C12N 15/88**; **C07J 9/00**; **C07J 41/00**

IPC 8 full level
A61K 9/127 (2006.01); **A61K 48/00** (2006.01); **C07J 41/00** (2006.01); **C12N 15/87** (2006.01)

CPC (source: EP)
A61K 9/1272 (2013.01); **A61K 48/00** (2013.01); **C07J 41/0055** (2013.01); **C07J 41/0061** (2013.01); **C12N 15/87** (2013.01)

Citation (search report)
See references of WO 0111068A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
FR 2797188 A1 20010209; AU 6849500 A 20010305; CA 2381224 A1 20010215; EP 1218033 A2 20020703; WO 0111068 A2 20010215; WO 0111068 A3 20020502

DOCDB simple family (application)
FR 9910141 A 19990804; AU 6849500 A 20000803; CA 2381224 A 20000803; EP 00956608 A 20000803; FR 0002234 W 20000803